To support biotechnology education for secondary school students, and for other purposes.

This bill, introduced on April 14, 2026, in the 119th Congress by Rep. McBride (D-DE), establishes a new section within the CHIPS and Science Act to authorize competitive grants for biotechnology education in secondary schools. The bill creates no direct revenue or cost for any publicly traded company. It is currently at the earliest legislative stage—referred to the House Committee on Science, Space, and Technology—with only three total actions (introduction and referral). No funding amount is authorized; the bill simply permits the Director of the relevant agency to make awards, subject to future appropriation.

The money trail is nonexistent at this stage. Authorization bills set policy but do not allocate funds; this bill lacks even a specific authorized ceiling. Actual spending would require a separate appropriations bill that has not been introduced. No procurement, tax credit, regulation, or mandate touches any company.

Structural market impact is zero. No tickers meet the causal chain specificity threshold because the bill does not reference any company, product, or technology by name. The long-term effect of improved biotechnology education could theoretically expand the labor pool for companies like Thermo Fisher Scientific ($TMO), Agilent Technologies ($A), Illumina ($ILMN), or CRISPR Therapeutics ($CRSP), but such an impact would take years of appropriations and implementation before any measurable revenue effect. This does not meet the threshold for actionable analysis.

Timeline: The bill must pass committee, then the full House, then the Senate (or move as part of a larger package), then be signed into law. Even if enacted, appropriations are a separate process. No significant legislative action is expected in the near term.